Hetero Labs filed an application with the Central Drugs Standard Control Organisation (CDSCO) last week. The CDSCO may soon reach out to ICMR for suggestions.
In science, establishing that something doesn’t work is as crucial as finding a solution. This is why most Covid-19 clinical trials are repurposing existing drugs.
Cipla, Hetero Labs, Jubilant Lifesciences & Mylan have now been allowed by remdesivir’s patent holder, Gilead, to produce the drug that has shown promise in Covid-19 treatment.
Under the licensing agreement, Jubilant will have the right to receive a technology transfer of the manufacturing process to scale up remdesivir production.
Drug has shown benefits in reducing recovery time for some patients, and the govt has asked companies if they’re in touch with Gilead Sciences for a licence.
Gilead Sciences plans a global consortium of pharma firms for production. It says decision of partnership will depend on how fast the drug’s supply can be ramped up.
For an industry globally classified as hazardous, protections such as health insurance and a provident fund for workers are necessities. In Sivakasi, they remain elusive.
The industry forecasts exports are set to grow 16% in 2025-26, boosted by surplus domestic production and a drive to push into 26 underserved global markets with strong potential.
Indigenisation level will progressively increase up to 60 percent with key sub-assemblies, electronics and mechanical parts being manufactured locally.
It is a brilliant, reasonably priced, and mostly homemade aircraft with a stellar safety record; only two crashes in 24 years since its first flight. But its crash is a moment of introspection.
Hii I need a remdesivir 100 mg I.v